There is a real opportunity for artificial intelligence to dramatically transform the speed, cost and efficiency of drug development over the long term, but the uptake of AI tools across biopharma has been much slower relative to the broader healthcare environment, SoftBank’s Jacqueline Fok said on The BioCentury Show. In conversation with BioCentury's Stephen Hansen, Fok, who is investment director, Life Sciences & Health Tech at SoftBank Investment Advisers, also detailed SoftBank’s investment strategy in life sciences and the opportunity the U.K. has to stand out as a globally competitive player, with SoftBank’s obesity portfolio company Metsera as a recent example of success.
Podden och tillhörande omslagsbild på den här sidan tillhör
BioCentury. Innehållet i podden är skapat av BioCentury och inte av,
eller tillsammans med, Poddtoppen.
